Brought to you by:
WVS 2021: Community surgeons report improved rAAA survival after adoption of EVAR-first approach
Overall survival improved from 71% to 80% after a group of community practice surgeons started using an endovascular-first approach to ruptured abdominal aortic aneurysm (rAAA) repair. Scott S. Berman, MD, a vascular surgeon at Pima Heart & Vascular in Tucson,…
The top 10 most popular Vascular Specialist stories in September
Five-year data from the ACST-2 trial comparing carotid endarterectomy and carotid artery stenting, a report from the Crawford Forum at the 2021 Vascular Annual Meeting (VAM), and an Eastern Vascular Society (EVS) annual meeting piece reporting on vascular surgery as…
Three-year VIVO results back ‘continued safety and effectiveness’ of Zilver Vena venous stent
Three-year results of the VIVO clinical study support the continued safety and effectiveness of the Zilver Vena venous stent (Cook Medical) in the treatment of symptomatic iliofemoral venous outflow obstruction, attendees at the Vascular Interventional Advances (VIVA) 2021 (Oct. 5–7) in Las Vegas.…
SVS task force continues fight to stop cuts
The Society for Vascular Surgery (SVS) Medicare Cuts Task Force is continuing its work to stop the proposed cuts in physician reimbursement from going through as planned in 2022. The task force was created to respond to the proposed 2022…
Registry data show greater clot chronicity on post-procedure inspection than initially predicted
Nearly half of patients deemed pre-procedurally to be suffering an acute case of deep vein thrombosis (DVT) turned out to have a “much more” chronic classification of the condition following intraoperative imaging and thrombus inspection post-procedure, an interim analysis from…
PROMISE I 24-month results ‘validate the benefits of the LimFlow system’
LimFlow has announced 24-month results from the PROMISE I study of the LimFlow percutaneous deep vein arterialization system, confirming “excellent and sustained outcomes” for both amputation-free survival and wound healing, a press release reports. The late-breaking data were presented at…
‘TCAR yields high technical success with an extraordinarily low stroke and death rate at one year’
Outcomes in a cohort of patients who consented to one year of follow-up after transcarotid revascularization (TCAR) treatment for carotid stenosis in the ROADSTER 2 trial showed a 97.4% rate of technical success, no incidences of ipsilateral stroke and a…
Physicians, industry urged to tackle multifactorial stroke risk following thoracic endovascular procedures
As evidence builds on the importance of reducing the risk of stroke by removing residual air prior to thoracic endovascular aortic repair (TEVAR) procedures, the onus will be on surgeons and device manufacturers to minimize this risk, attendees of CX…
One-year results show ‘superior’ primary patency rate for Eluvia DES compared to bare metal stents
One-year results presented at Vascular Interventional Advances (VIVA) 2021 in Las Vegas (Oct. 5–7) from the EMINENT trial demonstrated the superiority of the Eluvia drug-eluting stent (DES) system (Boston Scientific) compared to self-expanding bare metal stents for the treatment of…
IN.PACT AV DCB sustained ‘superior’ effectiveness in subgroups with high reintervention rates out to two years
Several subgroups of patients treated with the IN.PACT AV drug-coated balloon (DCB) for arteriovenous fistulas (AVFs) demonstrated a “statistically significant” higher rate of target lesion primary patency (TLPP) compared to those who underwent standard percutaneous transluminal angioplasty (PTA) through 24…